BsUFA II: Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act

Why It Matters

Enhanced transparency reduces regulatory uncertainty for biosimilar developers, accelerating market entry and fostering competition that can lower drug costs. The program’s measurable assessments guide future policy refinements, strengthening the FDA’s collaborative oversight model.

Key Takeaways

• FDA adds structured communication windows for biosimilar BLA reviews
• Extra review clock time allows late-cycle issue resolution
• Interim and final assessments will measure program effectiveness
• Program aligns biosimilar review transparency with novel drug processes
• Commitment letter outlines detailed expectations for industry stakeholders

Pulse Analysis

The Biosimilar User Fee Act (BsUFA) was reauthorized in 2022 as BsUFA II, extending the fee structure that funds the FDA’s review of biosimilar biologics. A central promise of the new law is to bring the same level of procedural openness that the agency has cultivated for novel drugs to the biosimilar pathway. To that end, the FDA launched the Program for Enhanced Review Transparency and Communication, a framework designed to give applicants clearer milestones, more direct dialogue, and measurable performance metrics during the evaluation of 351(k) biologics license applications.

Key components of the program include scheduled communication points where sponsors can discuss data gaps, regulatory expectations, and post‑submission queries with the review team. The agency also added dedicated clock time, allowing reviewers to convene with applicants later in the review cycle without jeopardizing statutory deadlines. An interim assessment released in early 2021 and a final assessment published later this year evaluate whether these mechanisms have improved predictability, reduced review times, and increased overall efficiency. Both reports are publicly available for stakeholder scrutiny.

For biosimilar developers, the heightened transparency translates into faster decision‑making and reduced uncertainty around market entry, potentially lowering development costs and expanding patient access to lower‑priced biologics. Payers and manufacturers alike stand to benefit from a more competitive landscape as earlier approvals compress the time gap between reference product launch and biosimilar availability. Ongoing monitoring through the program’s assessments will inform future regulatory refinements, reinforcing the FDA’s commitment to a science‑based, collaborative approach that balances safety with timely access.